What is UgenTec?
UgenTec, now known as Velsera, serves as a cornerstone in the molecular diagnostics ecosystem. The company specializes in sophisticated automation software designed to streamline sample flow, enforce real-time quality control, and provide actionable operational insights. Its flagship FastFinder platform acts as a vendor-neutral integration layer, allowing clinical, veterinary, and pharmaceutical labs to harmonize disparate diagnostic technologies into a unified, high-performance workflow. By reducing manual intervention and minimizing human error, UgenTec enables laboratories to scale their testing capacity while maintaining rigorous regulatory compliance and data integrity standards.
How much funding has UgenTec raised?
UgenTec has raised a total of $13M across 3 funding rounds:
Private Equity
$1.4M
Angel/Seed
$2.3M
Series A
$9.3M
Private Equity (2015): $1.4M, investors not publicly disclosed
Angel/Seed (2016): $2.3M led by BNP Paribas Fortis
Series A (2018): $9.3M supported by KU Leuven, Gemma Frisius Fund, Herman Verrelst, Annie Vereecken, Lrm, and IMEC
Key Investors in UgenTec
Gemma Frisius Fund
A seed capital fund associated with KU Leuven, focusing on the commercialization of research and the support of spin-off companies emerging from the university's extensive academic network.
LRM
A venture capital provider based in Limburg that supports economic development through smart money investments and the management of business incubators for innovative startups.
BNP Paribas Fortis
A prominent Belgian banking institution providing comprehensive financial services and strategic capital solutions to support the growth of established and emerging enterprises.
What's next for UgenTec?
With the backing of major institutional and venture capital partners, UgenTec is well-positioned to expand its footprint in the global diagnostics market. The current enterprise-level funding context suggests a strategic pivot toward deeper integration with next-generation sequencing (NGS) technologies and the expansion of its cloud-based diagnostic suite. Future initiatives will likely focus on enhancing the interoperability of the FastFinder ecosystem, fostering partnerships with global instrument manufacturers, and accelerating the adoption of AI-driven diagnostic analytics. As the industry shifts toward personalized medicine, UgenTec's ability to provide scalable, reliable software infrastructure will remain a primary driver of its long-term competitive advantage and sustained market growth.
See full UgenTec company page
